to help power new phase of oncology research

LONDON, UK, Sep 17, 2024 – Medidata, a Dassault Systèmes brand, and the European Organization for Research and Treatment of Cancer (EORTC), announced a four-year extension to their partnership. The extended relationship will enable EORTC to further increase patient access to oncology clinical trials, make trial participation easier, and help to deliver new treatments to the market faster. EORTC is now leveraging 13 Medidata solutions, enabling their researchers to access and manage all clinical data in a single place and offering patients a seamless trial experience.

Vassilis Golfinopoulos, headquarters director, EORTC, said, “We chose the Medidata Platform to further expand our data management and patient engagement capabilities based on our years of experience working together. This partnership will enhance our support for oncology researchers as we collaborate on innovative ways of working with clinical trial data in the future.”

“This expansion benefits patients through an improved clinical trial experience, engaging with study activities on their personal mobile devices, while researchers will have the ability to make better decisions faster,” said Janet Butler, executive vice president, head of global sales, Medidata. “The integration of additional solutions, including Medidata Rave CTMS and Medidata Rave eTMF, will empower EORTC researchers with higher data quality, allowing them to shorten study timelines and deliver safer oncology trials for patients.”

For EORTC the expanded partnership also allows the exploration of a joint research and data collaboration with Medidata AI solutions in pursuit of improved standards of cancer care.

For more information, visit medidata.com.